Literature DB >> 6251750

Cefotaxime: in vitro activity and tentative interpretive standards for disk susceptibility testing.

P C Fuchs, A L Barry, C Thornsberry, R N Jones, T L Gavan, E H Gerlach, H M Sommers.   

Abstract

Tested against 9,412 recent clinical isolates, cefotaxime exhibited 8 to 64 times greater activity against the Enterobacteriaceae than did cephalothin and two to four times greater activity against Pseudomonas aeruginosa, but only one-half to one-eighth the activity of cephalothin against staphylococci. Using 420 different clinical isolates, but with comparable minimal inhibitory concentration (MIC) distributions, disk diffusion-MIC regression analyses were performed, using 5- and 30-micrograms cefotaxime disks. Cefotaxime MIC susceptible and resistant breakpoints of less than or equal to 8 and greater than 32 micrograms/ml are tentatively proposed. Based on the MIC breakpoints, the data showed the best discrimination among the three susceptibility categories (susceptible, indeterminate, and resistant) when the 30-micrograms cefotaxime disk was used. The zone diameter breakpoints as determined by the error rate-bounded method and regression analysis were greater than or equal to 23 mm for susceptible, 15 to 22 mm for indeterminate, and less than or equal to 14 mm for resistant.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6251750      PMCID: PMC283944          DOI: 10.1128/AAC.18.1.88

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  beta-lactamase stability of HR 756, a novel cephalosporin, compared to that of cefuroxime and cefoxitin.

Authors:  K P Fu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

2.  BL-S786, a new parenteral cephalosporin. II. In vitro antimicrobial activity comparison with six related cephalosporins.

Authors:  R N Jones; C Thornsberry; A L Barry; P C Fuchs; T L Gavin; E H Gerlach
Journal:  J Antibiot (Tokyo)       Date:  1977-07       Impact factor: 2.649

3.  Activity of HR 756 against Haemophilus influenzae, Bacteroides fragilis and Gram-negative rods.

Authors:  F A Drasar; W Farrell; A J Howard; C Hince; T Leung; J D Williams
Journal:  J Antimicrob Chemother       Date:  1978-09       Impact factor: 5.790

4.  Cefotoxime (HR 756) a new cephalosporin with exceptional broad-spectrum activity in vitro.

Authors:  J M Hamilton-Miller; W Brumfitt; A V Reynolds
Journal:  J Antimicrob Chemother       Date:  1978-09       Impact factor: 5.790

5.  Susceptibility tests of anaerobic bacteria: statistical and clinical considerations.

Authors:  C M Metzler; R M DeHaan
Journal:  J Infect Dis       Date:  1974-12       Impact factor: 5.226

6.  HR 756, the syn isomer of a new methoxyimino cephalosporin with unusual antibacterial activity.

Authors:  Y A Chabbert; A J Lutz
Journal:  Antimicrob Agents Chemother       Date:  1978-11       Impact factor: 5.191

7.  HR 756, a highly active cephalosporin: comparison with cefazolin and carbenicillin.

Authors:  R Wise; T Rollason; M Logan; J M Andrews; K A Bedford
Journal:  Antimicrob Agents Chemother       Date:  1978-12       Impact factor: 5.191

8.  In vitro activity of HR 756, a new cephalosporin compound.

Authors:  P M Shah; G Troche; W Stille
Journal:  J Antibiot (Tokyo)       Date:  1978-11       Impact factor: 2.649

9.  Human pharmacology of cefotaxime (HR 756), a new cephalosporin.

Authors:  R Lüthy; R Münch; J Blaser; H Bhend; W Siegenthaler
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

10.  In vitro of cefotaxime against cephalothin-resistant clinical isolates.

Authors:  H W Van Landuyt; M Pyckavet
Journal:  Antimicrob Agents Chemother       Date:  1979-07       Impact factor: 5.191

View more
  21 in total

Review 1.  Bacterial antibiotic resistance before and after clinical application in the United States.

Authors:  A L Barry; R N Jones
Journal:  Bull N Y Acad Med       Date:  1987-04

2.  Evaluation of the in vitro susceptibility of gram-negative bacilli to cefotaxime, over a period of 3 years.

Authors:  J Murillo; M Guzmán; R Isturiz; C Ocero
Journal:  Drugs       Date:  1988       Impact factor: 9.546

3.  Comparison of a beta-lactamase induction test with a test that detects low-frequency resistance to cefotaxime.

Authors:  R E Menzies; D MacCulloch
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

4.  Clinical experience with cefotaxime for the therapy of bacteremias due to gram-positive organisms.

Authors:  C J Schleupner
Journal:  Infection       Date:  1985       Impact factor: 3.553

5.  The effect of N-formimidoyl thienamycin, ceftazidime, cefotiam, ceftriaxone and cefotaxime on non-fermentative Gram-negative rods, Aeromonas, Plesiomonas and Enterobacter agglomerans.

Authors:  A von Graevenitz; C Bucher
Journal:  Infection       Date:  1982 Sep-Oct       Impact factor: 3.553

6.  Medium-dependent zone size discrepancies associated with susceptibility testing of group D streptococci against various cephalosporins.

Authors:  D F Sahm; C N Baker; R N Jones; C Thornsberry
Journal:  J Clin Microbiol       Date:  1983-10       Impact factor: 5.948

7.  Antimicrobial activity of amikacin combinations against Enterobacteriaceae moderately susceptible to third-generation cephalosporins.

Authors:  R N Jones; R R Packer
Journal:  Antimicrob Agents Chemother       Date:  1982-12       Impact factor: 5.191

Review 8.  Gram-positive superinfections following beta-lactam chemotherapy: the significance of the enterococcus.

Authors:  R N Jones
Journal:  Infection       Date:  1985       Impact factor: 3.553

9.  Comparative synergistic activity of cefoperazone, cefotaxime, moxalactam, and carbenicillin, combined with tobramycin, against Pseudomonas aeruginosa.

Authors:  L Mintz; W L Drew
Journal:  Antimicrob Agents Chemother       Date:  1981-02       Impact factor: 5.191

10.  In vitro studies with cefotaxime: disk diffusion susceptibility tests.

Authors:  S Shadomy; E L Chan
Journal:  J Clin Microbiol       Date:  1982-08       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.